Overview

A Phase I Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of AAPB for Injection

Status:
NOT_YET_RECRUITING
Trial end date:
2026-03-26
Target enrollment:
Participant gender:
Summary
This is a Phase I clinical to evaluate the safety and tolerability of single and multiple intravenous infusions of AAPB at different doses over 7 consecutive days.
Phase:
PHASE1
Details
Lead Sponsor:
Jiangsu Kanion Pharmaceutical Co., Ltd
Treatments:
Infusions, Intravenous
Injections